Your session is about to expire
← Back to Search
AMG 340 for Prostate Cancer
Study Summary
This trial is testing a new cancer treatment for men with prostate cancer that has spread and no longer responds to hormone therapy or other treatments. The goal is to find the best dose of the new treatment, which will be given alone (monotherapy). The study will first test the treatment in a small group of people to see if it is safe and what side effects it causes (dose escalation), and then in a larger group of people (dose expansion).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself and am up and about more than half of my waking hours.I have had at least 2 treatments for metastatic prostate cancer and my cancer has gotten worse.My prostate cancer has spread to my brain or spinal cord.I have been diagnosed with prostate cancer.My heart, liver, kidneys, and blood are all functioning well.I haven't had or been treated for another cancer that could affect this study in the last 2 years.I am on long-term medication to suppress my immune system.I have a serious brain or spinal cord condition.I have HIV, HBV, or HCV but it's under control or cured.I have undergone chemical or surgical castration.My cancer has shown signs of neuroendocrine features.My cancer has spread to other parts of my body.I have a history of serious heart problems.
- Group 1: Dose Escalation
- Group 2: Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently registered for this clinical trial?
"The sponsor, Teneobio Inc., needs to recruit 130 participants who meet the study's enrollment criteria. These patients will be sourced from UCSF in San Francisco and Florida Cancer Specialists located in Sarasota."
To what extent could TNB-585 endanger individuals?
"Based on the available evidence, TNB-585's safety is rated as a 1 since this is an early phase clinical trial. As such, there are limited data to support its efficacy and security."
Are there any vacancies left for this medical experiment?
"Yes, the trial is still open for enrolment. Its first posting was on April 29th 2021 and its details were last edited on July 14th 2022 per clinicaltrials.gov records."
Share this study with friends
Copy Link
Messenger